~~<i id='D9BCE51033'><strike id='D9BCE51033'><tt id='D9BCE51033'><pre id='D9BCE51033'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：explore 2025-10-02 10:05:28 - browse：7

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Diagnostic tests are hitting their mathematical limits

explore

leisure time

explore

knowledge

focus

BRENDANSMIALOWSKI/AFPviaGettyImagesCommunityHealthSystemsisfacinganewfederalprobeintoitshospitalbill

WSS

Fetal surgery at risk from Dobbs and new abortion restrictions

6 phony surgeries that take placebo to the extreme

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Takeda, Janssen join wearable maker to measure scratching

Pediatric cancer treatments threatened by a new FDA policy

Disappointing trial forces Pfizer to pivot on obesity medicine plans

hotspot

focus

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Virginia high school admissions case could be legal follow

Dario to buy mental health app maker Twill in cash and stock deal

Supreme Court strikes down use of affirmative action

Rep. Raul Ruiz on the physician shortage and more

Novavax promises a turnaround & Lilly roils the obesity market

Medicare inequities exacerbate Puerto Rico’s health disparities

Medical leaders decry Supreme Court decision on affirmative action

R1 RCM gets $5.8 billion buyout offer from private equity firm

leisure time

Fetal surgery at risk from Dobbs and new abortion restrictions

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Cigna, Humana reportedly in talks to merge

PBM reform efforts get punted in Congress

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

30 years of 'Listening to Prozac'

explore

explore

knowledge

focus